BERKELEY HEIGHTS, N.J., May 30 /PRNewswire-FirstCall/ -- Genta Incorporated announced that several abstracts related to Genasense(R) (oblimersen sodium) Injection, the Company’s lead anticancer compound, will be featured at the annual meeting of the American Society of Clinical Oncology (ASCO) in Atlanta, GA during June 2-6, 2006. The abstracts include the following:
Poster presentations: -- Pooled Safety Analysis of Oblimersen Alone or with Fludarabine and Cyclophosphamide in Patients with Advanced Chronic Lymphocytic Leukemia. Poster #FF9; Saturday, June 3, 2006, 8:00 am-12:00 pm; Building B, Level 1, Hall B5. -- Impact of Prognostic Markers on Outcomes in Patients with Advanced Chronic Lymphocytic Leukemia Treated with the Regimen of Fludarabine/Rituximab plus Oblimersen (Bcl-2 Antisense). Poster #FF7; Saturday, June 3, 2006, 8:00 am-12:00 pm; Building B, Level 1, Hall B5.
Each of these abstracts can be viewed on the ASCO website at: http://www.asco.org.
Publication: -- Clinical Characterization of First Cycle Reactions in Patients with Chronic Lymphocytic Leukemia Treated with Oblimersen. -- Baseline Serum Lactate Dehydrogenase Levels are Highly Predictive of Superior Outcomes in Patients with Advanced Melanoma: Results from Extended Follow-up from the Dacarbazine/Oblimersen (Bcl-2 Antisense) Multinational Trial. -- Oblimersen in Combination with Dacarbazine Prolongs Prognostic Factor- Adjusted Overall Survival (OS). -- A Phase II Trial of Oblimersen Sodium (G3139) in Combination with Doxorubicin (DOX) in Advanced Hepatocellular Carcinoma (HCC). -- A Phase I Study of G3139 (Genasense) in Combination with RICE Chemotherapy in Relapsed non-Hodgkin’s Lymphoma (NHL). About Genasense
Genasense inhibits production of Bcl-2, a protein made by cancer cells that is thought to block chemotherapy-induced apoptosis (programmed cell death). By reducing the amount of Bcl-2 in cancer cells, Genasense may enhance the effectiveness of current anticancer treatment. Genta is pursuing a broad clinical development program with Genasense evaluating its potential to treat various forms of cancer.
About Genta
Genta Incorporated is a biopharmaceutical company with a diversified product portfolio that is focused on delivering innovative products for the treatment of patients with cancer. The Company’s research platform is anchored by two major programs that center on oligonucleotides (RNA- and DNA- based medicines) and small molecules. Genasense(R) (oblimersen sodium) Injection is the Company’s lead compound from its oligonucleotide program. The Company has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration for the use of Genasense plus fludarabine and cyclophosphamide for treatment of patients with relapsed or refractory chronic lymphocytic leukemia (CLL). Genta has also completed a Marketing Authorization Application to the European Medicines Agency (EMEA) for use of Genasense plus dacarbazine for treatment of patients with advanced melanoma. The leading drug in Genta’s small molecule program is Ganite(R) (gallium nitrate injection), which the Company is exclusively marketing in the U.S. for treatment of symptomatic patients with cancer related hypercalcemia that is resistant to hydration. For more information about Genta, please visit our website at: http://www.genta.com.
This press release may contain forward-looking statements with respect to business conducted by Genta Incorporated. By their nature, forward-looking statements and forecasts involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. There are a number of factors that could cause actual results and developments to differ materially. For a discussion of those risks and uncertainties, please see the Company’s Annual Report/Form 10-K for 2005.
Genta Incorporated
CONTACT: Investor Relations: Tara Spiess, or Andrea Romstad, both of TSCommunications Group, LLC, info@genta.com, +1-908-286-3980; MediaRelations: Greg Tiberend, of Richard Lewis Communications, Inc.,+1-212-827-0020, all for Genta Incorporated
Web site: http://www.genta.com/
